SM 108

Known as: SM-108 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1982-1991
01219821991

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
The effects of 4-carbamoylimidazolium 5-olate (SM-108), an antipurine compound, on a human leukemia cell line, K562, were studied… (More)
Is this relevant?
1989
1989
A total of 165 patients were entered into this study and 140 were evaluate for effects and 165 for toxicities. Of 39 patients… (More)
Is this relevant?
1989
1989
Phase I study with a new oral purine antagonist, SM-108, was conducted in a total of 73 cases in a 5-day consecutive schedule… (More)
Is this relevant?
1988
1988
Eighteen patients in a high-blast group of myelodysplastic syndrome were treated with low-dose SM-108 (4-carbamoylimidazolium 5… (More)
Is this relevant?
1987
1987
SM-108 (4-carbamoylimidazolium-5-olate) is a new purine antagonist which blocks IMP dehydrogenase, the key enzyme of de novo GMP… (More)
Is this relevant?
1986
1986
Ehrlich carcinoma and P388 leukemia cells were rendered resistant to 4-carbamoylimidazolium 5-olate (SM-108), and assessments… (More)
Is this relevant?
1985
1985
The purpose of this paper is to analyze the available data on SM-108 (4-carbamoylimidazolium 5-olate) with respect to its… (More)
Is this relevant?
1985
1985
We investigated the antitumor effect of orally administered SM-108. The drug showed strong antitumor activities against Ehrlich… (More)
Is this relevant?
1983
1983
By designing optimal administration schedules, it was found that 4-carbamoylimidazolium 5-olate (SM-108) showed an excellent… (More)
  • table 1
  • table 3
  • table 5
  • table 4
  • table 6
Is this relevant?
1982
1982
The mechanism of action of 5-carbamoyl-1H-imidazol-4-yl piperonylate (SL-1250), which has a broad antitumor spectrum, was… (More)
Is this relevant?